Association between preserved ratio impaired spirometry and 1-year clinical outcomes in patients with bronchiectasis patients: A cohort study

IF 2.4 Q2 RESPIRATORY SYSTEM Respiratory investigation Pub Date : 2025-01-01 DOI:10.1016/j.resinv.2024.12.013
Fei Gao , Siqi He , Jing Li , Xiaoyue Wang , Xiaoting Chen , Xiaoning Bu
{"title":"Association between preserved ratio impaired spirometry and 1-year clinical outcomes in patients with bronchiectasis patients: A cohort study","authors":"Fei Gao ,&nbsp;Siqi He ,&nbsp;Jing Li ,&nbsp;Xiaoyue Wang ,&nbsp;Xiaoting Chen ,&nbsp;Xiaoning Bu","doi":"10.1016/j.resinv.2024.12.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Preserved Ratio Impaired Spirometry (PRISm) (defined as the ratio of forced expired volume in the first second to forced vital capacity (FEV1/FVC) greater than 0·70 with a FEV1 of less than 80% predicted) is associated with a higher risk of hospitalizations and mortality in the general population. However, less is known about whether PRISm is associated with adverse clinical outcomes in patients with bronchiectasis. We aimed to investigate whether PRISm is associated with adverse clinical outcomes in bronchiectasis patients.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study with inpatients admitted with acute exacerbations of bronchiectasis between January 2017 and January 2022. Clinical data including anthropometry, spirometry, laboratory, etiological and radiologic variables were collected. Patients were divided into the normal spirometry group, the PRISm group and the obstructive spirometry group. All patients were followed up for 1 year. The primary outcome was readmission of bronchiectasis at 1 year.</div></div><div><h3>Results</h3><div>Of 487 bronchiectasis patients, we found 142 (29.2%) had normal spirometry, 67 (13.8%) had PRISm and 278 (57.1%) had obstructive spirometry. Patients with obstructive spirometry were more likely to be male and to smoke, had higher fibrinogen values and more lobes affected. Patients with PRISm (HR 1.929, 95% CI 1.049 to 3.546) and obstructive spirometry (HR 2.406, 95%CI 1.506 to 3.845) had a higher risk of readmissions compared with those with normal spirometry after adjustment for potential confounders.</div></div><div><h3>Conclusions</h3><div>PRISm was associated with significant increased risk for readmissions in patients with bronchiectasis compared with normal spirometry, which should receive special attention.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 163-169"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524002004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Preserved Ratio Impaired Spirometry (PRISm) (defined as the ratio of forced expired volume in the first second to forced vital capacity (FEV1/FVC) greater than 0·70 with a FEV1 of less than 80% predicted) is associated with a higher risk of hospitalizations and mortality in the general population. However, less is known about whether PRISm is associated with adverse clinical outcomes in patients with bronchiectasis. We aimed to investigate whether PRISm is associated with adverse clinical outcomes in bronchiectasis patients.

Methods

We performed a retrospective cohort study with inpatients admitted with acute exacerbations of bronchiectasis between January 2017 and January 2022. Clinical data including anthropometry, spirometry, laboratory, etiological and radiologic variables were collected. Patients were divided into the normal spirometry group, the PRISm group and the obstructive spirometry group. All patients were followed up for 1 year. The primary outcome was readmission of bronchiectasis at 1 year.

Results

Of 487 bronchiectasis patients, we found 142 (29.2%) had normal spirometry, 67 (13.8%) had PRISm and 278 (57.1%) had obstructive spirometry. Patients with obstructive spirometry were more likely to be male and to smoke, had higher fibrinogen values and more lobes affected. Patients with PRISm (HR 1.929, 95% CI 1.049 to 3.546) and obstructive spirometry (HR 2.406, 95%CI 1.506 to 3.845) had a higher risk of readmissions compared with those with normal spirometry after adjustment for potential confounders.

Conclusions

PRISm was associated with significant increased risk for readmissions in patients with bronchiectasis compared with normal spirometry, which should receive special attention.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
支气管扩张患者保留比例受损肺活量与1年临床结果的关系:一项队列研究。
背景:保存比受损肺活量测定法(PRISm)(定义为第一秒强制呼气容积与强制肺活量(FEV1/FVC)的比值大于0.70,FEV1低于预测的80%)与一般人群较高的住院和死亡风险相关。然而,PRISm是否与支气管扩张患者的不良临床结果相关尚不清楚。我们的目的是研究PRISm是否与支气管扩张患者的不良临床结果相关。方法:我们对2017年1月至2022年1月期间因支气管扩张急性加重住院的患者进行了回顾性队列研究。临床资料包括人体测量、肺活量测定、实验室、病因学和放射学变量。患者分为正常肺活量测定组、PRISm组和阻塞性肺活量测定组。所有患者均随访1年。主要终点为1年后支气管扩张再入院。结果:487例支气管扩张患者中,正常肺量142例(29.2%),PRISm肺量67例(13.8%),阻塞性肺量278例(57.1%)。阻塞性肺活量测定患者多为男性、吸烟、纤维蛋白原值较高、肺叶受影响较多。校正潜在混杂因素后,PRISm (HR 1.929, 95%CI 1.049 ~ 3.546)和阻塞性肺量计(HR 2.406, 95%CI 1.506 ~ 3.845)患者再入院风险高于正常肺量计患者。结论:与正常肺活量测定相比,PRISm与支气管扩张患者再入院风险显著增加相关,应引起特别注意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respiratory investigation
Respiratory investigation RESPIRATORY SYSTEM-
CiteScore
4.90
自引率
6.50%
发文量
114
审稿时长
64 days
期刊最新文献
Challenges in recognizing airway-centered fibrosis: Observer concordance and its role in fibrotic hypersensitivity pneumonitis Sarcomatoid pleural mesothelioma evaluated using diffusion-weighted whole-body imaging with background body signal suppression The clinical impact of acute vasoreactivity testing in patients with severe pulmonary hypertension associated with lung disease: A retrospective exploratory analysis Chronic obstructive pulmonary disease and healthy life expectancy Successful treatment by switching from benralizumab to dupilumab in a patient with allergic bronchopulmonary mycosis caused by Schizophyllum commune
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1